Zhejiang Starry Pharm Co Ltd (603520) - Total Assets
Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) holds total assets worth CN¥6.27 Billion CNY (≈ $918.15 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 603520 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Zhejiang Starry Pharm Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Zhejiang Starry Pharm Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Zhejiang Starry Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Starry Pharm Co Ltd's total assets of CN¥6.27 Billion consist of 36.9% current assets and 63.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.8% |
| Accounts Receivable | CN¥479.86 Million | 7.8% |
| Inventory | CN¥1.19 Billion | 19.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥291.24 Million | 4.7% |
| Goodwill | CN¥404.96 Million | 6.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zhejiang Starry Pharm Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Starry Pharm Co Ltd's current assets represent 36.9% of total assets in 2025, a decrease from 48.9% in 2011.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, up from 6.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 4.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 19.4% of total assets.
Zhejiang Starry Pharm Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Starry Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Zhejiang Starry Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.83 | 1.27 |
| Quick Ratio | 0.53 | 0.44 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥53.61 Million | CN¥-461.57 Million | CN¥384.96 Million |
Zhejiang Starry Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Starry Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | CN¥6.16 Billion |
| Market Capitalization | $610.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Starry Pharm Co Ltd's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Starry Pharm Co Ltd's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Starry Pharm Co Ltd (2011–2025)
The table below shows the annual total assets of Zhejiang Starry Pharm Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.16 Billion ≈ $900.70 Million |
+1.81% |
| 2024-12-31 | CN¥6.05 Billion ≈ $884.66 Million |
+9.59% |
| 2023-12-31 | CN¥5.52 Billion ≈ $807.23 Million |
+4.04% |
| 2022-12-31 | CN¥5.30 Billion ≈ $775.88 Million |
+8.31% |
| 2021-12-31 | CN¥4.90 Billion ≈ $716.35 Million |
+11.10% |
| 2020-12-31 | CN¥4.41 Billion ≈ $644.79 Million |
+26.44% |
| 2019-12-31 | CN¥3.48 Billion ≈ $509.94 Million |
+13.63% |
| 2018-12-31 | CN¥3.07 Billion ≈ $448.77 Million |
+52.32% |
| 2017-12-31 | CN¥2.01 Billion ≈ $294.62 Million |
+6.33% |
| 2016-12-31 | CN¥1.89 Billion ≈ $277.08 Million |
+28.09% |
| 2015-12-31 | CN¥1.48 Billion ≈ $216.32 Million |
+28.50% |
| 2014-12-31 | CN¥1.15 Billion ≈ $168.35 Million |
+14.03% |
| 2013-12-31 | CN¥1.01 Billion ≈ $147.63 Million |
+22.23% |
| 2012-12-31 | CN¥825.38 Million ≈ $120.78 Million |
+13.99% |
| 2011-12-31 | CN¥724.08 Million ≈ $105.95 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more